Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.00 Average Target Price from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $20.00.

Several brokerages have issued reports on ENTA. Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th. JMP Securities restated a “market outperform” rating and set a $22.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 9th. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. cut their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after acquiring an additional 134,292 shares during the period. American Century Companies Inc. raised its position in Enanta Pharmaceuticals by 35.4% in the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 7,287 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Enanta Pharmaceuticals by 65.8% during the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after purchasing an additional 18,003 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after buying an additional 1,548 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after buying an additional 8,645 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Up 2.9 %

NASDAQ:ENTA opened at $12.63 on Friday. The stock has a 50 day moving average of $11.83 and a two-hundred day moving average of $13.05. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $17.80. The firm has a market cap of $267.49 million, a P/E ratio of -2.02 and a beta of 0.58.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The business had revenue of $17.97 million for the quarter, compared to analysts’ expectations of $17.44 million. During the same period in the previous year, the firm posted ($1.27) EPS. The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, research analysts forecast that Enanta Pharmaceuticals will post -5.3 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.